C M Quinn
Overview
Explore the profile of C M Quinn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Browne I, McLaughlin R, Weadick C, OSullivan S, McSorley L, Hadi D, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(1):189-199.
PMID: 39365509
Purpose: The treatment landscape of Oestrogen receptor-positive (ER-positive) breast cancer is evolving, with declining chemotherapy use as a result of Oncotype DX Breast Recurrence Score® testing. Results from the SWOG...
2.
Ramachandran P, Ramesh A, Creswell F, Wapniarski A, Narendra R, Quinn C, et al.
Nat Commun
. 2022 Mar;
13(1):1675.
PMID: 35354815
The epidemiology of infectious causes of meningitis in sub-Saharan Africa is not well understood, and a common cause of meningitis in this region, Mycobacterium tuberculosis (TB), is notoriously hard to...
3.
Salgado R, Peg V, Ruschoff J, Vincent-Salomon A, Castellano I, Perner S, et al.
Ann Oncol
. 2021 Aug;
32(11):1316-1321.
PMID: 34461263
No abstract available.
4.
McSorley L, Tharmabala M, Al Rahbi F, McSorley K, Chew S, Evoy D, et al.
Breast Cancer Res Treat
. 2021 Apr;
188(3):789-798.
PMID: 33835293
Purpose: Results from TAILOR-X suggest that up to 70% of hormone receptor-positive (HR+) node-negative (N0) ESBC patients (pts) may avoid chemotherapy (CT) with RS ≤ 25. We assess clinical and...
5.
Boland M, McVeigh T, OFlaherty N, Gullo G, Keane M, Quinn C, et al.
BJS Open
. 2018 Jun;
1(2):39-45.
PMID: 29951604
Background: Optimal evaluation and management of the axilla following neoadjuvant chemotherapy (NAC) in patients with node-positive breast cancer remains controversial. The aim of this study was to examine the impact...
6.
Boland M, Ni Cearbhaill R, Fitzpatrick K, Walsh S, Evoy D, Geraghty J, et al.
World J Surg
. 2016 May;
40(9):2157-62.
PMID: 27206399
Introduction: Axillary status remains an important prognostic indicator in breast cancer. Certain patients with a positive sentinel node (SLNB) may not benefit from axillary clearance (AC). Uncertainty remains if this...
7.
McCartan D, Prichard R, MacDermott R, Rothwell J, Geraghty J, Evoy D, et al.
Br J Surg
. 2016 Mar;
103(7):839-44.
PMID: 27004443
Background: The majority of women with breast cancer present with localized disease. The optimal strategy for identifying patients with metastatic disease at diagnosis remains unclear. The aim of this study...
8.
Cserni G, Wells C, Kaya H, Regitnig P, Sapino A, Floris G, et al.
Virchows Arch
. 2016 Jan;
468(4):473-81.
PMID: 26818833
Microinvasion is the smallest morphologically identifiable stage of invasion. Its presence and distinction from in situ carcinoma may have therapeutic implications, and clinical staging also requires the recognition of this...
9.
Tchrakian N, Flanagan L, Harford J, Gannon J, Quinn C
Virchows Arch
. 2015 Nov;
468(2):207-11.
PMID: 26521061
Accurate determination of tumour human epidermal growth factor receptor type 2 (HER2) status is critical for optimal treatment of breast cancer. In October 2013, the American Society of Clinical Oncology...
10.
Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, ODoherty A, et al.
Eur J Surg Oncol
. 2015 Mar;
41(5):641-6.
PMID: 25736863
Aims: Women with inherited pathogenic mutations in the BRCA1 or BRCA2 genes have up to an 85% risk of developing breast cancer in their lifetime. However, only about 20% of...